ライフサイエンスコーパス: immunoassay

1 ctroscopy, SERS) and a specific recognition (immunoassay).

2 idation and usage are unique to each type of immunoassay.

3 esting with a chemiluminescent microparticle immunoassay.

4 lts are validated using a different p-tau217 immunoassay.

5 simple and ultrasensitive cholera toxin (CT) immunoassay.

6 cific IgG antibody were quantified by enzyme immunoassay.

7 unodetection was performed using an in-house immunoassay.

8 combined IgM-IgG point-of-care lateral flow immunoassay.

9 of PRF lysates was further confirmed by IL6 immunoassay.

10 ng nanophosphor-based lateral flow (UCNP-LF) immunoassay.

11 kaline phosphatase (ALP)-labeled competitive immunoassay.

12 hereby the realization of ultrasensitive PEC immunoassay.

13 an established microfluidic electrochemical immunoassay.

14 n detection limit of the existing rapid EBOV immunoassay.

15 e-standing, fully automated DMF platform for immunoassay.

16 concentrations were measured using multiplex immunoassay.

17 side the coverage provided by a conventional immunoassay.

18 ., immunoprobing) in a large-format hydrogel immunoassay.

19 clinically validated electrochemiluninescent immunoassay.

20 nd plasma using a highly sensitive proteomic immunoassay.

21 ssay (ELISA) and a Luminex-based microsphere immunoassay.

22 nosorbent Assay (ELISA) and Chemiluminescent Immunoassay.

23 xide nanoparticle (NP)-based mass tag for MC immunoassays.

24 likelihood ratios of first- and second-line immunoassays.

25 IPS) and enzyme-linked immunosorbent (ELISA) immunoassays.

26 or the implementation of highly miniaturized immunoassays.

27 ured by 2 validated electrochemiluminescence immunoassays.

28 kers were measured by ProcartaPlex multiplex immunoassays.

29 (2k)-CD196) were fabricated and tested in MC immunoassays.

30 wer protein concentrations than conventional immunoassays.

31 r antigens usually limits the sensitivity of immunoassays.

32 refore similar to high-performance automated immunoassays.

33 , IGFBP-3, PAPP-A, and STC2 were measured by immunoassays.

34 ification of brain cytokines using multiplex immunoassays.

35 odies (Abs) for high-dimensional single-cell immunoassays.

36 to variability in Western blotting and other immunoassays.

37 were measured using electrochemiluminescence immunoassays.

38 unoassay [CIA]); (2) Bioplex 2200 (microbead immunoassay); (3) fluorescent treponemal antibody absorp

39 bsorption test (FTA-ABS); (4) INNO-LIA (line immunoassay); (5) LIAISON CIA; (6) Treponema pallidum pa

40 o 4-5 h for a regular ELISA) make the FO-SPR immunoassay a powerful assay for routine diagnosis of iT

41 As with any immunoassay, a portion of the measured Ab binding can be

42 s reveal for the first time that competitive immunoassays achieve their selectivity by taking advanta

43 ned linked to the full automatization of the immunoassay allowed the fast and accurate determination

44 Online coupling of a micromotor-based immunoassay and a microfluidic electrochemical detection

45 zheimer's disease (AD), involving a sandwich immunoassay and amperometric detection at disposable scr

46 and bone markers were measured by multiplex immunoassay and ELISA in serum samples and periodontal t

47 ripheral inflammation in DLB using multiplex immunoassay and flow cytometry concomitantly.

48 was laboratory tested for HRP2 by bead-based immunoassay and for P. falciparum 18S rDNA by photo-indu

49 Immunoassay and immunofluorescence staining were perform

50 We used a single molecule array immunoassay and log-transformed data to examine the rela

51 en components using multiplex ImmunoCAP ISAC immunoassay and specific IgE to hazelnut, Cor a 14, and

52 here were 16 treponemal assays evaluated: 13 immunoassays and 3 manual assays (fluorescent treponemal

53 affinity ECL sensors including aptasensors, immunoassays and DNA analysis, cytosensor, molecularly i

54 ays a significant role in the sensitivity of immunoassays and efficiency of protein isolation using a

55 uncooked and baked muffins using monoclonal immunoassays and IgE antibody binding before and after b

56 Immunoassays and mass spectrometry are powerful single-c

57 ophil activation and NETs were quantified by immunoassays and microscopy and correlated with parasite

58 an in-house standardised ELISA, a multiplex immunoassay, and a live severe acute respiratory syndrom

59 recognize distinct LAM epitopes, a one-sided immunoassay, and blinded cohorts.

60 mbinant antigen-based SGERPAxMap microsphere immunoassay, and some of them were further evaluated thr

61 lution (BMD), disk diffusion (DD), and PBP2a immunoassay, and the results were compared to mecA PCR r

62 ction or trapping of chemical pollutants, in immunoassays, and for the design of sensors.

63 Results from a panel of exploratory immunoassays (antibody-dependent cellular cytotoxicity,

64 We used an immunoassay approach to test samples for the presence of

65 organization of the protein corona using an immunoassay approach.

66 Sandwich immunoassays are achieved when captured analytes labeled

67 Linker-mediated immunoassays are also demonstrated to provide robust qua

68 Immunoassays are fundamental analytical tools in molecul

69 Immunoassays are important for the detection of proteins

70 Treponemal immunoassays are increasingly used for syphilis screenin

71 Since immunoassays are not able to distinguish NPY from its me

72 Although immunoassays are prone to antibody batch differences, de

73 er, point-of-care technologies and serologic immunoassays are rapidly emerging.

74 to develop and use a multiplexed microsphere immunoassay as a next generation screening tool for use

75 ibility of SERS as an alternative to current immunoassays as a screening tool for use in emergency ro

76 The highly porous gels also had lower immunoassay background signal than the benchmark (2x) an

77 s the potential to improve the efficiency of immunoassay based diagnostic platforms with reduced assa

78 ing fluorescence microscopy combined with an immunoassay based on fluorescence relocation to paramagn

79 We developed a multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology that comprised 1

80 w analytical applications, in particular for immunoassay-based detection systems.

81 Most commercially available enzyme immunoassay-based methods have limited sensitivity to de

82 eSC point-of-care test alongside a different immunoassay-based point-of-care test (SickleSCAN) and th

83 easured in 0-12-year-olds using a bead-based immunoassay before and after ivermectin mass drug admini

84 etect double labeled amplicons on a sandwich immunoassay by designing specific labeled primer pair an

85 ped a customizable contact printed multiplex immunoassay capable of simultaneously measuring up to fi

86 rity assay was the most sensitive free-toxin immunoassay, capable of providing CDI diagnosis in a sin

87 articular treponemal immunoassay (eg, enzyme immunoassays, chemiluminescence immunoassays, microbead

88 assays: (1) ADVIA Centaur (chemiluminescence immunoassay [CIA]); (2) Bioplex 2200 (microbead immunoas

89 tified through competitive inhibition enzyme immunoassay (CIEIA), showed maximum production at 136.3

90 were evaluated using the competitive Luminex immunoassay (cLIA) and total immunoglobulin G assay.

91 Here, we report a chemiluminescence immunoassay (CLIA) for multiparametric quantification of

92 antial fluorescence intensity enhancement in immunoassays compared to flat gold substrate.

93 occal testing, and the institutional cost of immunoassays compared to those of newer molecular method

94 Immunoassay confirmed the capacity of UDCA to reduce inf

95 Here, using conformation-dependent immunoassay, conformation stability assay, and protein-m

96 Thus, the FNanoBiT based homogeneous immunoassay could be used as a rapid, and simple tool fo

97 de)/Ni/PtNPs (platinum nanoparticles))-based immunoassay coupled to thin layer Au-based electrochemic

98 This polydisperse digital droplet immunoassay (ddIA) uses proximity ligation to remove the

99 ostic platforms utilizing ELISA technique or immunoassays depends highly on incubation times of the r

100 We assessed the performance of 3 immunoassays detecting anti-platelet factor 4 (PF4)/hepa

101 mpatible with each of the most commonly used immunoassay detection modalities.

102 With the sandwich immunoassay developed for mouse immunoglobulin G, detect

103 Ebola virus glycoprotein IgG capture enzyme immunoassay developed from a previously validated assay.

104 -Disk) was developed as a novel photothermal immunoassay device with the integration of a clip-magazi

105 However, conventional immunoassays do not provide sufficient information regar

106 lthy controls using electrochemiluminescence immunoassay (ECLIA).

107 dence to recommend one particular treponemal immunoassay (eg, enzyme immunoassays, chemiluminescence

108 e infections (CDIs) detected by toxin enzyme immunoassay (EIA) are more severe and have worse outcome

109 hat of a multistep algorithm using an enzyme immunoassay (EIA) for detection of glutamate dehydrogena

110 The addition of toxin enzyme immunoassay (EIA) to nucleic acid amplification tests, i

111 were tested in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests against

112 y serological assays including enzyme-linked immunoassay (EIA), complement fixation (CF) and immunodi

113 PCR tests, toxin antigen detection by enzyme immunoassay (EIA), toxigenic culture, and fecal calprote

114 tion assay (TPPA); and (7) Trep-Sure (enzyme immunoassay [EIA]), using a reference standard combining

115 screening, typically performed using enzyme immunoassays (EIAs), is invasive, sometimes socially una

116 stralia were compared to a commercial enzyme immunoassay (ELISA) and a recently described novel surro

117 e injury and repair, and growth factors with immunoassay (enzyme-linked immunosorbent assay and Lumin

118 Low-cost methods like lateral flow immunoassays exist but frequently suffer from poor sensi

119 novel use of Sofia influenza A+B fluorescent immunoassay (FIA), a rapid antigen-based influenza point

120 ngle antibody-based fluorescent lateral flow immunoassay (FLFIA) depending on non-radiative energy tr

121 he development of a homogeneous luminescence immunoassay (FNanoBiT assay) for detection of fumonisin

122 tandard two-tiered testing algorithm (enzyme immunoassay followed by Western blot).

123 Developing immunoassay for absolute quantitation of protein biomark

124 zation and to confirm the specificity of the immunoassay for detection of anti-ADAMTS13 autoantibodie

125 An immunoassay for detection of glycated hemoglobin (HbA1c)

126 s end, a fluorescence anisotropy competitive immunoassay for online insulin detection from single and

127 eloped and validated an ultrasensitive blood immunoassay for p-tau181.

128 Herein, we developed an electrochemical immunoassay for rapid and smart detection of SARS-CoV-2

129 s the first highly sensitive electrochemical immunoassay for SARS-CoV-2 detection in untreated saliva

130 er, we describe the development of an FO-SPR immunoassay for the detection of autoantibodies in plasm

131 arity) assay is an automated, ultrasensitive immunoassay for the detection of Clostridioides difficil

132 fluidic technology to demonstrate a one-step immunoassay for the detection of the cardiac marker trop

133 e report a dual-readout, AuNP-based sandwich immunoassay for the device-free colorimetric and sensiti

134 G-Test Carba 5 is a rapid in vitro multiplex immunoassay for the phenotypic detection and differentia

135 test probability with first- and second-line immunoassays for anti-PF4/heparin antibodies is accurate

136 l using naso-/oro-pharyngeal PCR testing and immunoassays for IgG antibodies.

137 Nevertheless, most conventional immunoassays for ochratoxin A (OTA), including commercia

138 le molecule array technology, ultrasensitive immunoassays for serum concentrations of t-tau, Nf-L, an

139 m-up mass spectrometry (MS) has complemented immunoassays for the compositional and immunogenic analy

140 ) and polyglutamine-independent HTT specific immunoassays for validation in human HD and control fibr

141 We used 3-dimensional ultramicroscopy and immunoassays for visualizing CAA and assessing Abeta in

142 Small-molecule detection in an immunoassay format generally employs competition or labe

143 A new immunoassay format using thermally induced defragmentati

144 A competitive immunoassay format was followed employing immobilization

145 ed for the detection of FB1 in a competitive immunoassay format without the need of a secondary antib

146 arameters, used enzymes and redox mediators, immunoassay formats and analytical parameters of enzymat

147 e plasmon resonance and fluorescent sandwich immunoassay formats is discussed.

148 nzymatically-tagged competitive and sandwich immunoassay formats on a single chip platform.

149 gardless of the target molecules, in various immunoassay formats, such as enzyme-linked immunosorbent

150 using, as appropriate, classic bacteriology, immunoassays, gel-based PCR and reverse transcriptase PC

151 a new, highly sensitive lab on a chip (LOC) immunoassay has been designed, developed, and characteri

152 The developed impedance-based immunoassay has potential to significantly improve the C

153 The SHG primary immunoassay has provided the first kinetic measurements

154 is novel Au@Pt/Au NPs-based electrocatalytic immunoassay has the advantage, over common methods for N

155 Immunoassays have been used for decades in clinical labo

156 Current serological immunoassays have inherent limitations for certain infec

157 Bead-based immunoassays have shown great promise for rapid and sens

158 Cytokines are commonly measured by immunoassays; however, these have limited multiplexing c

159 nia (HIT) based on the 4Ts score and 2 rapid immunoassays (IAs) that correctly classified >95% of pat

160 nd is compatible with multiplexed bead-based immunoassays, immunomicroarrays, flow cytometry and immu

161 leased IMMY Aspergillus galactomannan enzyme immunoassay (IMMY GM-EIA) when testing serum samples and

162 dies into a bead-based fluorescence sandwich immunoassay implemented in a custom microfluidic chip.

163 , superior to the standard chemiluminescence immunoassay in cardiovascular clinics.

164 ochemistry and electrochemiluminescent-based immunoassays in the frontal cortex from foetuses to adul

165 Fe(CN)(6)(4-/3-) electrochemical probe after immunoassays in the presence of the biomarker.

166 The rest of the magneto-immunoassay, including sample filtration, MB washing and

167 Both the protein and immunoassays indicated a decrease in protein solubility

168 Subsequent chemiluminescence enzyme immunoassays indicated that they were positive for the S

169 We aimed to validate a tear MMP-9 in-situ immunoassay (InflammaDry) and to identify factors that c

170 ditional heterogeneous assays, a homogeneous immunoassay is a preferred format for its simplicity.

171 osensor and commercialized chemiluminescence immunoassay kits in clinical serum detection.

172 colonies: (i) the NG-Test MCR-1 lateral flow immunoassay (LFA; NG Biotech, Guipry, France) and (ii) t

173 f the spike protein (S1), and a lateral flow immunoassay (LFI) based on full-length spike protein.

174 l/chemiluminescence format of a lateral flow immunoassay (LFIA) immunosensor for IgA in serum and sal

175 It is based on sandwich-format lateral flow immunoassay (LFIA) of immunoglobulins as a biomarker for

176 rdetella pertussis infection by lateral flow immunoassay (LFIA).

177 incorporates the simplicity of lateral flow immunoassays (LFIA) utilizing plasmonic enhancement.

178 Sandwich lateral flow immunoassays (LFIAs) are limited at high antigen concent

179 of the BioPlex 2200 MMRV IgG multiplex flow immunoassay (MFI; Bio-Rad Laboratories, Hercules, CA) an

180 The multiplexed immunoassay (MIA) is an automated, monoclonal antibody-b

181 (eg, enzyme immunoassays, chemiluminescence immunoassays, microbead immunoassays) over another based

182 Therefore, the proposed SERS immunoassay might be implemented as a highly efficient t

183 lf-propelled micromotors, a micromotor-based immunoassay (MIm) has smartly been designed for C-reacti

184 uation of a multiplexed magnetic microsphere immunoassay (MMIA) to simultaneously detect immunoglobul

185 Using the same concept, two different immunoassay modalities were evaluated, using either magn

186 ple of biomolecule sensing, a competitive FP immunoassay of Prostaglandin E(2) was demonstrated using

187 nduced by a range of agents was evaluated by immunoassays of neural protein biomarkers.

188 ELISA with ICECEA as a signal transducer for immunoassays offers a rapid method for the selective det

189 ting proteins were quantified by a multiplex immunoassay (Olink) and used to recapitulate systemic in

190 It involves a plasmonic sandwich immunoassay on a U-bent fiber optic probe with gold plas

191 parison to conventional ELISA-based sandwich immunoassays on microtiter plates, our microfluidic setu

192 ntified from urine samples using a multiplex immunoassay or from positive blood cultures.

193 which counted only confirmed CDAD (by toxin immunoassay or nucleic acid amplification test) as failu

194 y improves usability compared to traditional immunoassays or digital-based systems that rely heavily

195 Unlike the traditional antibody-based immunoassays, our approach is capable of monitoring in-s

196 s, chemiluminescence immunoassays, microbead immunoassays) over another based on published performanc

197 Using multiplexed immunoassay panels and ELISA, 26 biomarkers were assesse

198 ative 8-OHdG detection with the lateral flow immunoassay paper sensor and smartphone camera demonstra

199 nanoparticle-based colorimetric lateral flow immunoassay paper sensor for quantifying urine 8-hydroxy

200 Lateral flow immunoassay paper strips quantitatively measure 8-OHdG a

201 ods used for allergen detection are based on immunoassays, PCR and mass spectrometry.

202 f gel pore size on IEF separation and in-gel immunoassay performance.

203 ions, we have developed a simplified digital immunoassay performed in polydisperse droplets that are

204 ntigen (CEA) by measuring the end-product of immunoassay performed on magnetic particles.

205 Also, highlighted is a novel, self-contained immunoassay platform (the D4 assay) that transforms time

206 able to demonstrate QDB method as the first immunoassay platform for absolute quantitation of protei

207 enna assay sensor is developed as an on-chip immunoassay platform for ultrasensitive detection of Ebo

208 The magnetically-assisted SERS immunoassay presented a better performance and was there

209 ti-GBS antibodies were measured by multiplex immunoassay prevaccination and 30/60 days postvaccinatio

210 This immunoassay protocol makes thousands of low-abundance pr

211 tiple binding steps in conventional sandwich immunoassay protocols result in high assay hands-on-time

212 Single-molecule (digital) immunoassays provide the ability to detect much lower pr

213 Herein we propose a photothermal immunoassay (PTIA) by taking mycotoxins (AFB(1)) as an e

214 The enzyme immunoassay ratio decreased in controllers who had conti

215 To date, however, the utility of such immunoassays remains unclear.

216 opositive by both the point-of-care test and immunoassay reported a previous PCR test.

217 try and competitive electrochemiluminescence immunoassay, respectively, from baseline serum/plasma sa

218 MS) and competitive electrochemiluminescence immunoassay, respectively, from baseline serum/plasma sa

219 o 1250-fold more sensitive than LC-MS/MS and immunoassays, respectively.

220 lammatory biomarkers were measured by enzyme immunoassay.RESULTSSixty-nine participants (97% male, me

221 very vehicles, cell and tissue matrices, and immunoassay scaffolds that utilize hydrogel materials is

222 In general immunoassays, secondary antibodies are covalently linked

223 uality control sequencing metrics and higher immunoassay sensitivity, our results suggest that nasal

224 mperometric and fluorescence quenching-based immunoassays showed a linear response with a lowest dete

225 Immunoassays showed that the recognition of Der p 2 by t

226 mobilized target is responsible for >=50% of immunoassay signal loss, and that target loss is attribu

227 Using immunoassays specific for SARS-CoV-2 spike proteins, we

228 clonal antibodies, an optimized lateral flow immunoassay strip, and one-step aqueous extraction.

229 Furthermore, real-time and in-line immunoassay studies with a specially designed 3D printed

230 ardized antibody validation and reporting in immunoassays such as Western blotting may promote improv

231 entification and monitor treatment, but many immunoassays suffer from sensitivity limitations.

232 xample of sensitive, lower-cost, and simpler immunoassays suitable for both laboratory and point-of-c

233 ays were developed using the fully automated immunoassay system, HI-1000 and their significance over

234 eration in the same neutral medium where the immunoassay takes place (0.1 M PBS pH 7.2), avoiding the

235 oV-2 IgG antibody using the Abbott Architect immunoassay targeting the nucleocapsid protein were run

236 ocapsid protein were run in 3 SARS-CoV-2 IgG immunoassays targeting spike proteins (DiaSorin Liaison,

237 Immunoassays targeting tau fragments N-123, N-mid-region

238 e "fourth-generation" HIV-1 screening enzyme immunoassay (targeting the p24 antigen and anti-HIV-1 an

239 oglobulin E (IgE) levels were measured using immunoassay techniques in nasal secretions and nasal pol

240 een recently used to enhance the accuracy of immunoassay techniques.

241 he IgG avidity assay used a novel label-free immunoassay technology.

242 t is the first model of a traffic light-like immunoassay test strip based on Pdots with multiplexing

243 ed symptoms were verified and a lateral flow immunoassay test that detected SARS-CoV-2 immunoglobulin

244 tion of discordant results using CrAg enzyme immunoassay testing, the sensitivity was 98.1% (95% CI,

245 The platform was designed on a DNA-based immunoassay that employed conjugated antibodies for targ

246 pared the diagnostic accuracy of serological immunoassays that are based on various SARS-CoV-2 protei

247 k quantitative results or by high complexity immunoassays that are time- and labor-intensive but prov

248 Serological immunoassays that can identify protective immunity again

249 on achieved did not improve those of current immunoassays, the proposed methodology could provide pro

250 meric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 neutralisation assays

251 well beyond that of present state-of-the-art immunoassays, thus creating potential ECL applications i

252 Serum were screened using a multiplex immunoassay to detect antibodies reactive with the envel

253 rated the utility of a non-invasive salivary immunoassay to detect norovirus infections and an effici

254 We applied a multiplex immunoassay to serially collected saliva samples gathere

255 We used a multiplex salivary immunoassay to study norovirus infections among 483 visi

256 viral RNA or rapid diagnostic tests based on immunoassays to detect EBOV antigens.

257 del assay to quantify IgGs as well as in two immunoassays to determine the biomarkers C-reactive prot

258 To our knowledge, the combination of immunoassays to distinguish overlapping epitopes and nuc

259 Moreover, immunoassays to fluopyram were developed in two alternat

260 y, and serum was collected for enzyme-linked immunoassays to quantify peripheral HMGB1.

261 k and easy-to-operate method to make various immunoassays to sensitively detect low-abundance target

262 ed with anti-CD63 antibodies formed a direct immunoassay toward CD63-positive exosomes in 75% v/v ser

263 ocapsid antigen (Veritor), a chromatographic immunoassay used for SARS-CoV-2 point-of-care testing, w

264 ave developed a swift and simplistic protein immunoassay using aptamer functionalized AlGaN/GaN high

265 er's disease (AD) biomarker in a competitive immunoassay using magnetic bead (MB) platforms at levels

266 A cap fluorescence enzyme immunoassay using the serum of the patient showed specif

267 imated in vitro by a competitive fluorescent immunoassay using three pools of sera from peach allergi

268 A novel direct-detection label-free primary immunoassay utilizing second harmonic generation (SHG) h

269 The results of the MMP-9 in-situ immunoassay varied significantly depending on sample vol

270 nd antibody serology were analyzed by enzyme-immunoassays; viral load by PCR.

271 Immunoassay was applied to detect the production of IL6.

272 Our novel interleukin-19 (IL-19) immunoassay was initially tested to determine concentrat

273 A multiplex chemiluminescent immunoassay was performed to evaluate the concentrations

274 The immunoassay was successfully applied in a cohort of 140

275 The performance of the immunoassay was then evaluated by comparing Co(III)- and

276 Finally, the FO-SPR immunoassay was validated using seven iTTP patient plasm

277 luorescent protein targets and a single-cell immunoassay, we identify regimes in which nonuniformly d

278 Using a multiplex immunoassay, we measured interleukin (IL) 1beta, IL-6, t

279 peripheral blood mononuclear cells and serum immunoassays, we analyzed the effects of a 4 months pres

280 conjugate conventionally used in competitive immunoassays, we designed a ZEA mimicking peptide extend

281 Utilizing in vitro and in vivo immunoassays, we found that T cell responses were blunte

282 protein recovery and using highly sensitive immunoassays, we report the detection of different Nf-L

283 cashew, Ana o 3, using singleplex ImmunoCAP immunoassay were determined.

284 e analytical features of the electrochemical immunoassay were evaluated using the standard solution o

285 d by immunoblot and conformational stability immunoassay were indistinguishable.

286 The optimized immunoassays were applied to the analysis of fluopyram i

287 Hundreds of molecular tests and immunoassays were rapidly developed, albeit many still a

288 Immunoassays were used to quantify Chit-1, CHI3L1 and ph

289 Magnetic bead-based immunoassays were utilized to measure the concentrations

290 tamate dehydrogenase and toxin A or B enzyme immunoassays) were randomly assigned (1:1) with a random

291 monstrated high accuracy of the calorimetric immunoassay when compared with gold standard commercial

292 y understood, particularly in IHC and in-gel immunoassays, where immobilized targets are heterogeneou

293 D and S1 protein of SARS-CoV-2 are promising immunoassays which shall be further evaluated in studies

294 signals could be obtained with conventional immunoassay, while electrokinetic mixing still facilitat

295 OFL-TIIA is a fast, sensitive, and low-cost immunoassay with a simple homogeneous and wash-free proc

296 the most promising candidates by IgG4-based immunoassays with sensitivities of 53% for rOVOC10469 an

297 binding sites were assessed and compared by immunoassays with three previously studied murine IgG mA

298 the point-of-care test and 4.6% (4.3-5.0) by immunoassay, with a specificity-sensitivity range of 3.7

299 led a customizable contact printed multiplex immunoassay workflow.

300 sults across all species, although the PBP2a immunoassay yielded 100% correlation.